Coding and Reimbursement Updates
This Month’s E-Reiumbursement Newsletter from Bobbi Buell for January 2026.
READ MORE
FDA Approvals
FDA approved new, flexible dosing regimens for TEVIMBRA® (tislelizumab-jsgr) from BeOne Medicines USA.
READ MORE
Updates from ASCO
ASCO Chief Medical Officer Julie Gralow warns that unstable federal funding is causing a "cancer brain drain" that threatens America’s scientific leadership and the future of life-saving breakthroughs.
READ MORE
Rates of multiple myeloma, the second most common blood cancer in the United States, are increasing and are twice as high in men than in women. A new study published in the journal Cancer provides insights that may help to explain this disparity.
READ MORE
The Centers for Medicare & Medicaid Services released two proposed drug pricing models—Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD)—intended to reduce Medicare spending by aligning U.S. drug prices with international pricing benchmarks. Both models target high-cost, single-source drugs, which includes many chemotherapy and immunotherapy agents.
READ MORE
